Spirodihydantoin Is a Minor Product of 5-Hydroxyisourate in Urate Oxidation
摘要:
Spirodihydantoin is a minor product from oxidation of uric acid (similar to0.15% yield), while spiroiminodihydantoin is a major product from oxidation of 8-oxo-7,8-dihydroguanine (37% yield, pH 10.2). High pH and temperature favor the formation of both spiro compounds. O-18 labeling experiments and in situ generation and decomposition of 5-hydroxy-N7-methylisouric acid indicate that spirodihydantoin and allantoin and spiroiminodihydantoin and guanidinohydantoin are products of 5-hydroxyisourate and 5-hydroxy-8-oxo-7,8-dihydroguanine intermediates, respectively.
5-Carboxamido-5-formamido-2-iminohydantoin, in Addition to 8-oxo-7,8-Dihydroguanine, Is the Major Product of the Iron-Fenton or X-ray Radiation-Induced Oxidation of Guanine under Aerobic Reducing Conditions in Nucleoside and DNA Contexts
作者:Omar R. Alshykhly、Aaron M. Fleming、Cynthia J. Burrows
DOI:10.1021/acs.joc.5b00689
日期:2015.7.17
ine (cyclo-dG), and the free base guanine (Gua). Reactions conducted with ascorbate or N-acetylcysteine as a reductant under aerobic conditions identified d2Ih as the major lesion formed. Studies were conducted to identify the role of O2 and the reductant in product formation. From these studies, mechanisms are proposed to support d2Ih as a majoroxidationproduct detected under aerobic conditions
Spirodihydantoin Is a Minor Product of 5-Hydroxyisourate in Urate Oxidation
作者:Hongbin Yu、Jacquin C. Niles、John S. Wishnok、Steven R. Tannenbaum
DOI:10.1021/ol048547w
日期:2004.9.1
Spirodihydantoin is a minor product from oxidation of uric acid (similar to0.15% yield), while spiroiminodihydantoin is a major product from oxidation of 8-oxo-7,8-dihydroguanine (37% yield, pH 10.2). High pH and temperature favor the formation of both spiro compounds. O-18 labeling experiments and in situ generation and decomposition of 5-hydroxy-N7-methylisouric acid indicate that spirodihydantoin and allantoin and spiroiminodihydantoin and guanidinohydantoin are products of 5-hydroxyisourate and 5-hydroxy-8-oxo-7,8-dihydroguanine intermediates, respectively.